VANI (Vivani Medical) Tariff Resilience Score: 6/10 (As of Sep. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VANI Vivani Medical Inc VANI
33 GF Score
Price $1.32
! 1 Warning Sign
View Full Analysis

What is Vivani Medical Tariff Resilience Score?

Vivani Medical VANI -2.59% 33 Tariff Resilience Score is 6 as of Sep. 09, 2026. GuruFocus rates VANI with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 1,358 Biotechnology companies, Vivani Medical ranks better than 75.99% on this metric.

Vivani Medical has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Vivani Medical has Vivani Medical Inc's exposure to tariffs is moderate due to its reliance on international components for medical devices. However, its niche market and potential for alternative suppliers provide some resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Vivani Medical might have Average Resilient.

Vivani Medical  (NAS:VANI) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Vivani Medical Tariff Resilience Score Related Terms

VANI vs BDTX, VTVT, TLSA: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Vivani Medical's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vivani Medical Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vivani Medical's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Vivani Medical's Tariff Resilience Score falls into.


VANI
33GF Score
Vivani Medical Inc VANI
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Vivani Medical (VANI) has a Tariff Resilience Score of 6 as of Sep. 09, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Vivani Medical ranks #326 out of 1358 companies in the Biotechnology industry, placing it in the top 24%.
Is Vivani Medical's Tariff Resilience Score too high?
Vivani Medical's current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Vivani Medical's value of 6 is 50% above this industry median. Based on the distribution chart, Vivani Medical ranks #326 out of 1358 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vivani Medical has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Vivani Medical's Tariff Resilience Score compare to BDTX and VTVT?
According to the Biotechnology industry distribution chart, Vivani Medical ranks #326 out of 1358 companies for Tariff Resilience Score. This places Vivani Medical in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Vivani Medical's value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,358 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vivani Medical's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivani Medical's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivani Medical stock overvalued right now?
Vivani Medical (VANI) has a current Tariff Resilience Score of 6. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Vivani Medical's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Vivani Medical (VANI), the current Tariff Resilience Score is 6 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vivani Medical Business Description

Other Exchanges U5P:Germany
Address 1350 South Loop Road, Alameda, CA, USA, 94502
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.
33GF Score

Get the complete analysis for VANI

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.32
Price